CANDEL THERAPEUTICS INC (CADL)
US1374041093 - Common Stock
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
Let's take a look at the stocks that are in motion in today's session.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease...
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
/PRNewswire/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for...
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC...
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
/PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood...
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...
CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
Candel Therapeutics just reported results for the first quarter of 2024.
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical...
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!